Concepedia

Publication | Open Access

Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks

DOIFull Paper Access

70

Citations

19

References

2019

Year

Sazan Rasul, Marcus Hacker, Elisabeth Kretschmer‐Chott, Asha Leisser, Bernhard Grubmüller, Gero Kramer, Shahrokh F. Shariat, Wolfgang Wadsak, Markus Mitterhauser, Markus Hartenbach,
European Journal of Nuclear Medicine and Molecular Imaging

Abstract

Intense PSMA-RLT regime with four weekly intervals between the cycles is well-tolerated and offers favorable response rates, PFS, and survival rates for patients with mCRPC.

References

YearCitations

Page 1